Literature DB >> 27347128

Downregulation of SENP1 inhibits cell proliferation, migration and promotes apoptosis in human glioma cells.

Qiu-Sheng Zhang1, Meng Zhang1, Xian-Jian Huang1, Xiao-Jia Liu1, Wei-Ping Li1.   

Abstract

Small ubiquitin-related modifier protein (SUMO) is an evolutionarily conserved protein in a broad range of eukaryotic organisms. De-SUMOylation, the reverse reaction of SUMOylation, is regulated by a family of SUMO-specific proteases (SENPs). SENP1 is a member of the de-SUMOylation protease family involved in the de-SUMOylation of a variety of SUMOylated proteins. The present study demonstrates that small hairpin RNA (shRNA)-mediated downregulation of SENP1 inhibits cell proliferation and migration, and promotes apoptosis in human glioma cells. Firstly, LN-299 cells were transfected with a plasmid expressing SENP1 shRNA (pGenesil-1-SENP1). The messenger RNA and protein expression of SENP1 was detected by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. Cell proliferation in vitro was assessed using a methyl thiazolyl tetrazolium assay. Flow cytometry (FCM) was used to detect the apoptosis of LN-299 cells. The effect of the downregulation of SENP1 on cell migration was detected by a Transwell migration system. The present results showed that, compared with the control shRNA group, the expression of SENP1 was significantly reduced in the SENP1 shRNA group. The proliferation was markedly inhibited in the SENP1 shRNA group. FCM findings revealed that apoptosis increased significantly in the SENP1 shRNA group. In addition, it was found that downregulation of SENP1 evidently suppressed tumor cell migration. Downregulation of SENP1 expression inhibited the proliferation and migration and promoted apoptosis in LN-299 cells. These results indirectly demonstrate that SENP1 is likely to play a critical role in human glioma cells.

Entities:  

Keywords:  SENP1; apoptosis; glioma; migration; proliferation; shRNA

Year:  2016        PMID: 27347128      PMCID: PMC4907169          DOI: 10.3892/ol.2016.4558

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

Review 1.  SUMO: a history of modification.

Authors:  Ronald T Hay
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

Review 2.  Role of desumoylation in the development of prostate cancer.

Authors:  Jinke Cheng; Tasneem Bawa; Peng Lee; Limin Gong; Edward T H Yeh
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

Review 3.  SUMO-specific proteases: a twist in the tail.

Authors:  Ronald Thomas Hay
Journal:  Trends Cell Biol       Date:  2007-09-04       Impact factor: 20.808

Review 4.  Concepts in sumoylation: a decade on.

Authors:  Ruth Geiss-Friedlander; Frauke Melchior
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

5.  SUMO-specific protease 1 promotes prostate cancer progression and metastasis.

Authors:  Q Wang; N Xia; T Li; Y Xu; Y Zou; Y Zuo; Q Fan; T Bawa-Khalfe; E T H Yeh; J Cheng
Journal:  Oncogene       Date:  2012-06-25       Impact factor: 9.867

6.  SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms.

Authors:  Tasneem Bawa-Khalfe; Jinke Cheng; Sue-Hwa Lin; Michael M Ittmann; Edward T H Yeh
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

7.  Coregulator exchange and sphingosine-sensitive cooperativity of steroidogenic factor-1, general control nonderepressed 5, p54, and p160 coactivators regulate cyclic adenosine 3',5'-monophosphate-dependent cytochrome P450c17 transcription rate.

Authors:  Eric B Dammer; Adam Leon; Marion B Sewer
Journal:  Mol Endocrinol       Date:  2006-11-22

8.  Pregnane X receptor is SUMOylated to repress the inflammatory response.

Authors:  Gang Hu; Chenshu Xu; Jeff L Staudinger
Journal:  J Pharmacol Exp Ther       Date:  2010-08-18       Impact factor: 4.030

9.  SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR.

Authors:  Benoit Pourcet; Inés Pineda-Torra; Bruno Derudas; Bart Staels; Corine Glineur
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

10.  Sentrin/SUMO specific proteases as novel tissue-selective modulators of vitamin D receptor-mediated signaling.

Authors:  Wai-Ping Lee; Sarita Jena; Declan Doherty; Jaganathan Ventakesh; Joachim Schimdt; Julie Furmick; Tim Widener; Jana Lemau; Peter W Jurutka; Paul D Thompson
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

View more
  4 in total

1.  A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer.

Authors:  Danielle M Bouchard; Michael J Matunis
Journal:  J Gastrointest Oncol       Date:  2019-10

2.  SUMO targeting of a stress-tolerant Ulp1 SUMO protease.

Authors:  Jennifer Peek; Catherine Harvey; Dreux Gray; Danny Rosenberg; Likhitha Kolla; Reuben Levy-Myers; Rui Yin; Jonathan L McMurry; Oliver Kerscher
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

3.  SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways.

Authors:  Yanfang Yang; Ziwei Liang; Zijing Xia; Xixi Wang; Yanni Ma; Zenghua Sheng; Qingjia Gu; Guobo Shen; Liangxue Zhou; Hongxia Zhu; Ningzhi Xu; Shufang Liang
Journal:  Cell Commun Signal       Date:  2019-07-25       Impact factor: 5.712

4.  SENP1 is required for the growth, migration, and survival of human adipose-derived stem cells.

Authors:  Yingying Wu; Beixin Yu; Min Wang
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.